4541.T
Latest Trade
1,228.00JPYChange
-51.00(-3.99%)Volume
559,500Today's Range
-
1,256.0052 Week Range
-
1,907.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 1,279.00 |
|---|---|
Open | 1,255.00 |
Volume | 559,500 |
3M AVG Volume | 4.32 |
Today's High | 1,256.00 |
Today's Low | 1,217.00 |
52 Week High | 1,907.00 |
52 Week Low | 1,072.00 |
Shares Out (MIL) | 63.76 |
Market Cap (MIL) | 83,343.03 |
Forward P/E | 11.61 |
Dividend (Yield %) | 2.35 |
Sagent Pharmaceuticals Announces FDA Acceptance Of Omega Manufacturing Site
Nichi-Iko Pharmaceutical announces exercise of options
Nichi-Iko Pharmaceutical announces exercise of options
Nichi-Iko Pharmaceutical Co.,Ltd. is a Japan-based company principally engaged in the manufacture and sale of generic pharmaceutical products and other medical products. The Company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed.
Industry
Biotechnology & Drugs
Executive Leadership
Yuichi Tamura
President, Representative Director
Kenji Akane
Executive Vice President, Director
Noboru Inazaka
Senior Managing Executive Officer, Chief Director of Administration, Director
Takahiro Yoshikawa
Managing Executive Officer, Chief Director of Procurement, Director
Toru Ishizu
Managing Executive Officer, Chief Director of Development & Planning
Price To Earnings (TTM) | 12.59 |
|---|---|
Price To Sales (TTM) | 0.49 |
Price To Book (MRQ) | 0.71 |
Price To Cash Flow (TTM) | 5.15 |
Total Debt To Equity (MRQ) | 110.01 |
LT Debt To Equity (MRQ) | 78.29 |
Return on Investment (TTM) | 3.10 |
Return on Equity (TTM) | 2.12 |
* Says it will start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" on Nov. 29
Nichi-Iko Pharmaceutical Co Ltd * Says it merged with a wholly owned unit, on Oct. 1 Source text in Japanese:https://goo.gl/Zi3Hxh Further company coverage: (Beijing Headline News)
* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" from the Ministry of Labour, Health, and Welfare on Sept. 27
* Says it plans to merge with a wholly owned subsidiary, which is engaged in manufacture of pharmaceuticals
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.